Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 819-827 , December 2009

Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation

  • Mark E. Patterson, PhD, MPH

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • William C. Grant, PhD

      Affiliations

    • Department of Economics, James Madison University, Harrisonburg, Virginia
    • ,
  • Seth W. Glickman, MD, MBA

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Barry M. Massie, MD

      Affiliations

    • San Francisco Veterans Affairs Medical Center and University of California, San Francisco
    • ,
  • Susan E. Ammon, MS, RN, FNP

      Affiliations

    • San Francisco Veterans Affairs Medical Center and University of California, San Francisco
    • ,
  • Paul W. Armstrong, MD

      Affiliations

    • University of Alberta, Edmonton
    • ,
  • John G.F. Cleland, MD

      Affiliations

    • Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-Upon-Hull, United Kingdom
    • ,
  • Joseph F. Collins, SCD

      Affiliations

    • Cooperative Studies Program Coordinating Center, VA Maryland Health Care System, Perry Point, Maryland
    • ,
  • Koon K. Teo, MBBCH, PhD

      Affiliations

    • McMaster University Medical Center, Hamilton, Ontario
    • ,
  • Kevin A. Schulman, MD

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Shelby D. Reed, PhD

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
    • Corresponding Author InformationReprint requests: Shelby D. Reed, PhD, Center for Clinical Genetics and Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. Tel: (919) 668-8101; Fax: (919) 668-7124

Received 7 July 2008 ,Revised 1 May 2009 ,Accepted 1 July 2009.

References 

  1. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10:101–112
  2. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616–1624
  3. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116:797–806
  4. Badia X, Bueno H, González Juanatey JR, Valentín V, Rubio M. [Short-and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev Esp Cardiol. 2005;58:1385–1395[In Spanish.]
  5. Lamy A, Jönsson B, Weintraub WS, Zhao F, Chrolavicius S, Bakhai A, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil. 2004;11:460–465
  6. Latour-Pérez J, Navarro-Ruiz A, Ridao-López M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health. 2004;7:52–60
  7. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med. 2004;255:562–570
  8. Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther. 2005;27:100–110
  9. Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006;151:219–227
  10. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45:838–845
  11. Office of National Statistics. Focus on Consumer Price Indices: July 2007. London: Office of National Statistics; 2007. Available at: http://www.statistics.gov.uk/downloads/theme_economy/FocusonCPI_June_2007.pdf. Accessed August 8, 2007.
  12. Statistics Canada. Consumer Price Index, Health and Personal Care, by Province (Canada). Available at: http://www40.statcan.ca/l01/cst01/econ161a.htm. Accessed August 8, 2007.
  13. Bureau of Labor Statistics, US Department of Labor. Consumer Price Index. Available at: http://www.bls.gov/cpi/. Accessed August 8, 2007.
  14. Organization for Economic Cooperation and Development. Purchasing Power Parities (PPP). Available at: http://www.oecd.org/std/ppp. Accessed August 8, 2007.
  15. Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care. 2003;19:396–406
  16. Centers for Medicare & Medicaid Services. PFS Carrier Specific Files: North Carolina, 2004. Available at: http://www.cms.hhs.gov/PhysicianFeeSched/PFSCSF/. Accessed June 4, 2008.
  17. National Grouping System Categories Report, Canada, 2003-2004. Toronto: Canadian Institute for Health Information; 2006.
  18. Bamezai A, Melnick G. Marginal cost of emergency department outpatient visits: an update using California data. Med Care. 2006;44:835–841
  19. Dong SL, Bullard MJ, Meurer DP, Blitz S, Akhmetshin E, Ohinmaa A, et al. Predictive validity of a computerized emergency triage tool. Acad Emerg Med. 2007;14:6–15
  20. Radeva JI, Reed SD, Kaló Z, Kauf TL, Cantu E, Cretin N, et al. Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. Clin Transplant. 2005;19:122–129
  21. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol. 2005;28:8–16
  22. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1:54–77
  23. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157–164
  24. Meune C, Mahé I, Mourad JJ, Cohen-Solal A, Levy B, Kevorkian JP, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail. 2003;5:271–279
  25. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115–119
  26. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000;109:371–377
  27. Takkouche B, Etminan M, Caamano F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf. 2002;25:373–378
  28. MacIntrye IM, Jhund PS, McMurray JJ. Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovasc Drugs Ther. 2005;19:261–265
  29. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581–588
  30. Parry D, Fitzmaurice D, Raftery J. Anticoagulation management in primary care: A trial-based economic evaluation. Br J Haematol. 2000;111:530–533
  31. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study. Ann Pharmacother. 2005;39:446–451
  32. Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: A pharmacoeconomic analysis. Pharmacoeconomics. 2006;24:593–607

 All decisions regarding this manuscript were made by a guest editor.

 The WATCH trial was conducted under the auspices of the US Department of Veterans Affairs Cooperative Study Program, with partial unrestricted support from Bristol-Myers Squibb Company and Sanofi-Aventis.

PII: S1071-9164(09)00681-2

doi: 10.1016/j.cardfail.2009.07.004

Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 819-827 , December 2009

Article Tools